Cargando…

The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma

BACKGROUND: Advanced gastric cancer (GC) is a lethal malignancy, harboring recurrent alterations in cell cycle pathway, especially the CDKN2A-CDK4/CDK6/CCND1 axis. However, monotherapy of CDK4/6 inhibitors has shown limited antitumor effects for GC, and combination treatments were urgently needed fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Mei, Xu, Hao, Zhou, Wenyuan, Pan, Yisheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909925/ https://www.ncbi.nlm.nih.gov/pubmed/36755269 http://dx.doi.org/10.1186/s13046-023-02615-2

Ejemplares similares

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
por: Miller, Aubrey L., et al.
Publicado: (2021)

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring
por: Qu, Mingli, et al.
Publicado: (2018)

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
por: Benito, E, et al.
Publicado: (2017)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1
por: Decker, Tim-Michael, et al.
Publicado: (2017)

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells
por: Sui, Shiyao, et al.
Publicado: (2019)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer
por: Pang, Yingxin, et al.
Publicado: (2022)

VDAC1 is regulated by BRD4 and contributes to JQ1 resistance in breast cancer
por: Yang, Guochao, et al.
Publicado: (2019)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

JQ1 as a BRD4 Inhibitor Blocks Inflammatory Pyroptosis-Related Acute Colon Injury Induced by LPS
por: Chen, Ling, et al.
Publicado: (2021)

Targeting SIRT1 synergistically improves the antitumor effect of JQ-1 in hepatocellular carcinoma
por: Jiang, Yuancong, et al.
Publicado: (2023)

Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
por: Jung, Marie, et al.
Publicado: (2014)

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
por: Stewart, Helen Jayne Susan, et al.
Publicado: (2013)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Inhibition of Brd4 by JQ1 Promotes Functional Recovery From Spinal Cord Injury by Activating Autophagy
por: Li, Yao, et al.
Publicado: (2020)

Small Molecule BRD4 Inhibitors Apabetalone and JQ1 Rescues Endothelial Cells Dysfunction, Protects Monolayer Integrity and Reduces Midkine Expression
por: Shahid, Sidra, et al.
Publicado: (2022)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states
por: Handoko, Lusy, et al.
Publicado: (2018)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Instant jqGrid
por: Manricks, Gabriel
Publicado: (2013)

JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis
por: Lee, Min Bum, et al.
Publicado: (2017)

Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects
por: Kim, Young Hun, et al.
Publicado: (2021)

Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9
por: Kottom, Theodore J., et al.
Publicado: (2022)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Abemaciclib for breast cancer
Publicado: (2020)

Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget’s Disease
por: Takahashi, Gary W, et al.
Publicado: (2022)

Bromodomain inhibitor JQ1 reversibly blocks IFN-γ production
por: Gibbons, Hunter R., et al.
Publicado: (2019)

Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas
por: Tanaka, Yuka, et al.
Publicado: (2020)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
por: Sun, Chao-Yue, et al.
Publicado: (2022)

LncRNA LBX2-AS1 impacts osteosarcoma sensitivity to JQ-1 by sequestering miR-597-3p away from BRD4
por: Li, Jiayu, et al.
Publicado: (2023)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment
por: Marchesi, Irene, et al.
Publicado: (2022)

Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1
por: Orekhova, Anastasia, et al.
Publicado: (2022)

Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
por: Pan, Yu, et al.
Publicado: (2019)

Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth
por: Zhang, Lian, et al.
Publicado: (2015)

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
por: Yang, Yan, et al.
Publicado: (2020)

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
por: Fujiwara, Hiroaki, et al.
Publicado: (2018)

The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells
por: Garcia, Patrick L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f1ac29kf1g6ldqfo6po77bb8ld